

RESULTS OF ANNUAL GENERAL MEETING

Melbourne, Australia, 29 November 2023: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) held the 2023 Annual General Meeting (AGM) today at 10.00am (AEDT).

Voting for all resolutions tabled at the AGM was conducted by poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, details of the resolutions and proxies received for the meeting are set out in the attached proxy summary.

Authorised by the Company Secretary, Mark Edwards.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
Chief Executive Officer
E Ihinch@inovig.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome capture tools and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, see www.inovig.com.

FORWARDING LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.



INOVIQ Limited

Annual General Meeting Wednesday, 29 November 2023

Results of Meeting



The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	24,563,408	154,564	1,804,394	227,675	26,404,802	154,564	227,675	Carried
		92.62%	0.58%	6.80%	1 ¹	99.42%	0.58%	ı'	(l]'
2A Re-election of Geoff Cumming as Non-executive Director	Ordinary	25,620,888	92,614	1,804,394	382,853	27,462,282	92,614	382,853	Carried
		93.10%	0.34%	6.56%	·	99.66%	0.34%	ı <u> </u>	<u> </u>
2B Election of David Williams as Non-executive Director	Ordinary	26,047,229	19,230	1,818,071	16,219	27,902,300	19,230	16,219	Carried
		93.41%	0.07%	6.52%	(¹	99.93%	0.07%	ı'	
3 Approval of 10% Placement Capacity	Special	25,373,618	489,885	1,804,394	232,852	27,215,012	489,885	232,852	Carried
		91.71%	1.77%	6.52%	ı ,	98.23%	1.77%	'	1
4 Issue of options to Non-executive Director - Mr David Williams	Ordinary	19,875,482	1,260,038	1,810,174	68,384	21,722,656	1,260,038	68,384	Carried
		86.62%	5.49%	7.89%		94.52%	5.48%	<u> </u>	

^{*} Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

